Researchers have developed a new approach to T cell therapy that is more effective and less toxic than current treatments. This new approach uses bispecific T cell engagers (BITEs) to redirect T cells to target and kill cancer cells. The researchers found that this approach was more effective than traditional T cell therapy and did not cause the same level of side effects. This is good news for patients with multiple myeloma, as it could lead to more effective and safer treatments.
Funding
This work was supported by Mahidol University through the Basic Research Fund for Fiscal Year 2023 (FF-026/2566) and by Siriraj Research Funds, Grant numbers R016334002 and R016737004, from the Faculty of Medicine Siriraj Hospital, Mahidol University (through PY). All authors are affiliated with the Thailand Hub of Talents in Cancer Immunotherapy (TTCI). KS, PL, and PY academic activities are supported by the National Research Council of Thailand (N34E670096).
Original Paper
Title of original paper: Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells
Journal: International Immunopharmacology
DOI: https://doi.org/10.1016/j.intimp.2024.113480